[go: up one dir, main page]

van der Vleuten, 2007 - Google Patents

Familial Combined Hyperlipidemia. A complex multifactoral lipid disorder.

van der Vleuten, 2007

View PDF
Document ID
4830614626026563632
Author
van der Vleuten G
Publication year

External Links

Snippet

Familial combined hyperlipidemia (FCH) is a multifactorial disease, characterized by the presence of multiple lipid and lipoprotein phenotypes, including hypercholesterolemia, hypertriglyceridemia and hyperapobetalipoproteinemia. Decreased levels of high-density …
Continue reading at repository.ubn.ru.nl (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Similar Documents

Publication Publication Date Title
Al Safar et al. Vitamin D receptor gene polymorphisms among Emirati patients with type 2 diabetes mellitus
Adams et al. Association between liver‐specific gene polymorphisms and their expression levels with nonalcoholic fatty liver disease
EP1833988B1 (en) Novel genes and markers associated to type 2 diabetes mellitus
EP1978107A1 (en) Fto gene polymorphisms associated to obesity and/or type II diabetes
US8017324B1 (en) ENPP1 (PC-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications
Peters et al. A mouse model for cystinuria type I
EP2013365B1 (en) Use of the ornithine transcarbamylase (otc), as a marker for diagnosing brain damages
EP2501826A1 (en) Nutrigenetic biomarkers for obesity and type 2 diabetes
Love-Gregory et al. Higher chylomicron remnants and LDL particle numbers associate with CD36 SNPs and DNA methylation sites that reduce CD36
Polonikov et al. A Common Polymorphism G‐50T in Cytochrome P450 2J2 Gene Is Associated with Increased Risk of Essential Hypertension in a Russian Population
Li et al. Variation in IGF2BP2 interacts with adiposity to alter insulin sensitivity in Mexican Americans
WO2008144940A1 (en) Biomarker for hypertriglyceridemia
EP2367951A1 (en) Compositions and methods for treating growth hormone deficiency
van der Vleuten et al. Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia
US10174377B2 (en) Method for diagnosing and assessing risk of pancreatitis using genetic variants
Parchwani et al. Influence of genetic variability at the ACE locus in intron 16 on Diabetic Nephropathy in T1DM patients
van der Vleuten Familial Combined Hyperlipidemia. A complex multifactoral lipid disorder.
WO2012024189A2 (en) Compositions and methods for determining predisposition to developing metabolic syndrome
US8236497B2 (en) Methods of diagnosing cardiovascular disease
US20140004510A1 (en) Methods and compositions for prognosing and/or detecting age-related macular degeneration
Hendig et al. Identification of a xylosyltransferase II gene haplotype marker for diabetic nephropathy in type 1 diabetes
EP2894229A1 (en) Markers related to age-related macular degeneration and uses therefor
US20080194419A1 (en) Genetic Association of Polymorphisms in the Atf6-Alpha Gene with Insulin Resistance Phenotypes
Diakou et al. Original research Characterization of low density lipoprotein receptor (LDLR) gene mutations in Albania
Li Variation in insulin-like growth factor-2 binding protein 2 interacts with adiposity to alter insulin sensitivity in Mexican Americans